The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Results from the EPO-Pretar trial: impact of early vs delayed ESA initiation in patients with LR-MDS
Sophie Park, MD, PhD, CHU Grenoble Alpes, Grenoble, France, discusses results from the Phase III EPO-Pretar trial (NCT03223961) investigating the impact of early versus delayed ESA initiation in patients with lower-risk myelodysplastic syndromes (LR-MDS). Dr Park highlights that although there was no difference in transfusion dependence between the early and delayed arms, the erythroid response rate was higher in the early arm (85% versus 55%). She also comments on the use of the ESA-IPSS-M score to calculate a patient’s response duration to ESAs. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
